At the news
? BEARISHIMPACT 7/10 PRESS-RELEASE filed May 13, 2026 at 16:35 ET
Reviva Pharmaceuticals reported Q1 2026 net loss of $3.2M ($0.46/share), narrower than the year-ago $6.4M loss ($2.61/share), but the EPS of -$0.46 missed the consensus estimate of -$0.29 by 58.6%. The company is advancing its brilaroxazine program with FDA feedback expected mid-2026 and RECOVER-2 Phase 3 enrollment in Q3 2026, but its stock is transitioning from Nasdaq to OTCQB effective May 14, 2026, which severely limits liquidity and access to capital.
- Q1 2026 net loss of $3.2M ($0.46/share) vs $6.4M ($2.61/share) in Q1 2025
- EPS of -$0.46 missed consensus estimate of -$0.29 by 58.6%
- Cash and equivalents $22.2M as of March 31, 2026, up from $14.4M at year-end 2025
- Common stock transitioning from Nasdaq to OTCQB effective May 14, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access